1. BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
- Author
-
Rajesh M. Valanparambil, Lilin Lai, Margaret A. Johns, Meredith Davis-Gardner, Susanne L. Linderman, Tarrant Oliver McPherson, Andres Chang, Akil Akhtar, Estefany L. Bocangel Gamarra, Hayley Matia, Ashley A. McCook-Veal, Jeffrey Switchenko, Tahseen H. Nasti, Felicia Green, Manpreet Saini, Andreas Wieland, Benjamin A. Pinsky, Daniel Solis, Madhav V. Dhodapkar, Jennifer Carlisle, Suresh Ramalingam, Rafi Ahmed, and Mehul S. Suthar
- Subjects
Immunologic diseases. Allergy ,RC581-607 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract This study reports that most patients with NSCLC had a significant increase in the nAb response to the currently circulating Omicron variants after bivalent booster vaccination and had Ab titers comparable to healthy participants. Interestingly, though the durability of the nAb response persisted in most of the healthy participants, patients with NSCLC had significantly reduced nAb titers after 4โ6 months of vaccination. Our data highlight the importance of COVID-19 bivalent booster vaccination as the standard of care for patients with NSCLC given the evolution of new variants of concern.
- Published
- 2023
- Full Text
- View/download PDF